ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Roche will pay $2.4 billion to acquire the portion of genomic profiling firm Foundation Medicine that it doesn’t already own. Foundation develops tests that pinpoint the genetic defect driving a person’s cancer, allowing tailored treatments. Roche bought a majority stake in the firm in early 2015 for $1.3 billion. The deals dovetail with Roche’s strategy to focus on personalized health care. Foundation will operate as a separate entity.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X